GlobeNewswire Inc.··NaRadiopharm Theranostics Advances RAD202 Trial to Higher Dose Cohort
Radiopharm Theranostics advances RAD202 radiopharmaceutical trial to higher dose cohort following positive safety review, remaining on track for 2026 Phase 1 completion.
RADXPhase 1 clinical trialoncology